Market Value: BioMarin Corp (BMRN)

BioMarin Pharmaceutical Inc. - graphic logo of issuer BMRN

BioMarin Pharmaceutical (BMRN) focuses on developing therapies for individuals with rare genetic disorders, leveraging a robust scientific foundation and R&D. This price chart reflects a market capitalization of 11.29. The business prioritizes internal development, avoiding acquisitions. Simultaneously, the company is implementing energy-efficient solutions in its laboratories to reduce resource consumption and comply with environmental standards.

BMRN BioMarin: Market Capitalization in the range 07/04/2022 - 11/12/2026

Financial and market metric breakdowns for BioMarin Corp (BMRN)

- market price and analyst price targets:
Price Chart BioMarin|BMRN - Consensus Target
- company stock exchange capitalization indicators:
Market Value BioMarin Corp|BMRN - Value Adjusted for Debt and Cash
- book value of equity indicators:
Net Assets per Single Share BioMarin|BMRN - Accounting Capitalization|Market Value to Book Value Ratio biomarin.com|BMRN - Company Total Asset Base
- debt and solvency information:
Debt to Equity BioMarin Pharmaceutical|BMRN - Long-Term Liabilities to Equity|Short-Term Debt to Capital BioMarin Pharmaceutical|BMRN - Company Cumulative Debt|Debts to Book Capitalization BioMarin Corp|BMRN - Company Long-Term Liabilities|Company Short-Term Debts BioMarin|Quick Ratio biomarin.com
- business earnings and investment ratios data:
BMRN - Net Profit|Expected Profit BioMarin Pharmaceutical|BMRN - Price to Earnings Ratio|Forward P/E Multiple BioMarin Pharma|BMRN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio BioMarin Corp|BMRN - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) BioMarin|BMRN - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth biomarin.com|BMRN - Earnings per share growth this year|Expected earnings per share growth for next year BioMarin Pharmaceutical
Initial company analysis:BioMarin BMRN
Original product of BioMarin Corp

Conservative capital requires objective verification of asset values that excludes subjective expectations. This indicator measures the total market value of all shares, allowing for the determination of a fair acquisition price without overpaying for the brand. For BioMarin Pharmaceutical (BMRN), whose revenues depend on exclusive drugs for rare pathologies, the total market value of the business reflects the actual scale of monetization of its highly specialized portfolio.

Competitors of BioMarin Pharmaceutical (BMRN)

Market Value Vertex VRTX|ALNY - Market Valuation|INSM - Market Value|Market Value UTHR (United Therapeutics Inc.)|BridgeBio Pharma, Inc. (BBIO) - Market Value|Market Capitalization BGM|Market Value Cogent Biosciences, Inc.|Xeris Biopharma Holdings, Inc. (XERS) - Market Capitalization|Market Value Keros Pharma (KROS)|ARCT: Market Valuation|Market Capitalization ETON (Eton Pharmaceuticals)|kamada.com (KMDA) - Market Value|Fulcrum Therapeutics, Inc. - Market Capitalization|Abeona Therapeutics (ABEO) - Market Valuation|MREO: Market Capitalization|PLX - Market Capitalization|PLRX (Pliant Therapeutics Inc) - Market Capitalization|Market Capitalization Applied Therapeutics Inc.|Market Value Rein Therapeutics (RNTX)|Market Value GELS (gelteq.com)|Market Capitalization AYTU (Aytu BioPharma)|Market Capitalization Chemomab Therapeutics Ltd (CMMB)|SRXH: Market Valuation|Market Valuation PLRZ|AEZS: Market Capitalization|Market Value Cyclo Therapeutics Inc. (CYTH)|INZY (Inozyme Pharma Inc.) - Market Capitalization|Market Capitalization RPHM (Reneo Pharmaceuticals, Inc)|Market Valuation CSCI (COSCIENS Biopharma Inc.)